IO Biotech, Inc.
IOBT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | 0.05 | -0.18 | -0.02 |
| FCF Yield | -135.94% | -88.04% | -91.16% | -22.12% |
| EV / EBITDA | -0.03 | 0.65 | 1.06 | 0.40 |
| Quality | ||||
| ROIC | -197.50% | -68.08% | -51.15% | -19.47% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.86 | 0.83 | 0.84 | 0.60 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -14.34% | -19.27% | -48.09% | -309.79% |
| Safety | ||||
| Net Debt / EBITDA | 0.62 | 1.54 | 2.02 | 3.14 |
| Interest Coverage | 0.00 | 0.00 | -236.50 | -114.22 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -2,003.85 | -1,872.31 | -2,706.41 | 0.00 |